Ocular toxicity with TKI therapy in CML
AbstractTyrosine kinase inhibitors are the standard treatment for Chronic
Myeloid Leukemia. They have significantly improved the response rate and
global survival in the long term for CML patients, but also added
relevant and diverse toxicity. The authors report a clinical case of
ocular toxicity connected to the TKIs.